Ferumoxytol in clinical practice: Implications for MRI

Volume: 37, Issue: 6, Pages: 1476 - 1479
Published: Oct 23, 2012
Abstract
Ferumoxytol is an iron-containing parenteral treatment for iron deficiency anemia that was recently approved by the Food and Drug Administration. The iron is in the form of a superparamagnetic iron oxide that causes T1, T2, and T2* shortening on magnetic resonance imaging (MRI). Furthermore, the drug has a long intravascular half-life of 14–15 hours; a standard dose can affect MRI for days to months. We describe a case in which a patient...
Paper Details
Title
Ferumoxytol in clinical practice: Implications for MRI
Published Date
Oct 23, 2012
Volume
37
Issue
6
Pages
1476 - 1479
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.